Merck agreed to buy Acceleron Pharma Thursday in a deal that values the rare drug specialists at around $11.5 billion. Merck will pay $180 per share for Cambridge, Massachusetts-based Acceleron ...

Shares in Acceleron have been grown by the third in the last month, and closed on Friday at almost $168, not far off its 52-week high of $174. Image Phil Taylor ...

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.

Acceleron Bank Revolutionizes International Payments With NudgeConvert: Empowering Community Banks and Credit Unions To Generate Non-Interest Income. WHITE RIVER JUNCTION, VT / ACCESSWIRE / March ...

Global Eisenmenger Complex Management Industry is expected to reach US$ 12.9 Billion at a CAGR of 5.3% by 2033 | FMI Reveals ...

In this photo illustration, the Merck Sharp and Dohme logo is displayed on a ... [+] smartphone screen. (Photo Illustration ...

At the time of its Acceleron buyout, the company projected Winrevair, also known as sotatercept, would compete in a PAH drug ...

In Merck’s quarterly conference call on Thursday, it took CEO Rob Davis less than a minute to tout newly approved pulmonary ...

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming ...